Glans Filler: What the Evidence Shows

Glans filler means injection of a material—most often hyaluronic acid (HA) in published studies—into the glans penis. It is not the same as shaft filler for penile girth. The strongest clinical research has examined glans HA injection as a proposed treatment for premature ejaculation (PE) by reducing sensitivity, not as a routine cosmetic enlargement procedure. The 2026 EAU guideline states that HA glans injection can be used with caution for PE compared with more established treatments because serious complications are possible and additional safety data are needed.

Is glans filler the same as penile shaft filler?

No. The glans and shaft have different anatomy, tissue characteristics and vascular considerations.

• Shaft filler is mainly studied for penile girth enhancement.
• Glans filler has been studied mainly in relation to PE and sensitivity, with some literature describing augmentation of glans volume.

Evidence and risk from one site should not automatically be transferred to the other.

Read about penile shaft filler.

Why has HA been injected into the glans?

The proposed mechanism in PE studies is reduced tactile sensitivity. HA creates a tissue layer that may alter sensory stimulation reaching superficial receptors. Early studies and later controlled trials reported increases in intravaginal ejaculatory latency time (IELT) in selected men.

However, PE is multidimensional. Diagnosis is not based only on penile sensitivity or stopwatch time; it also considers control, distress and interpersonal impact.

Read about premature ejaculation assessment.

Does glans filler treat premature ejaculation?

It has evidence of effect in some studies, but it is not a first-line standard equivalent to established PE therapies.

The current EAU guideline:

• recognises controlled studies showing modest improvement in IELT and patient-reported outcomes;
• notes that serious complications can occur;
• recommends HA injection with caution compared with more established treatment modalities.

EAU first-line pharmacological options for lifelong PE include dapoxetine in countries where approved and a metered-dose lidocaine/prilocaine spray in the EU. The appropriate approach also depends on whether PE is lifelong or acquired and whether erectile dysfunction, prostatitis or other conditions are present.

What does the 2024 meta-analysis add?

A 2024 systematic review and meta-analysis evaluated HA gel injection into the glans for PE. It supports that the technique can increase ejaculation latency in studied populations, but the literature remains relatively small and heterogeneous. That makes the intervention an evidence-informed but still cautious option—not a procedure that should be marketed as a predictable cure.

What about cosmetic glans enlargement?

Published literature includes glans augmentation, but the evidence base for purely cosmetic glans volume enhancement is less established than the literature on shaft girth filler and the PE-focused studies. A patient asking for a larger glans should therefore be told that aesthetic outcome evidence, standard volume and long-term safety are not as clearly defined.

Is there a standard filler or amount?

No universal product or dose is established for all patients. Historical studies used specific HA products and volumes under research protocols, but those protocols should not be copied into general patient guidance.

The glans is not a site where “more volume” can be assumed to produce a better result. Tissue pressure and vascular safety are particularly important.

Why should PE be assessed before an injection?

Someone asking for glans filler “to last longer” may have:

• lifelong PE;
• acquired PE;
• variable early ejaculation that is within normal variation;
• erectile dysfunction that leads to rushing intercourse;
• prostatitis or other genitourinary symptoms;
• anxiety or relationship factors.

These have different management pathways. Treating the glans without defining the problem can bypass more established and less invasive options.

Who may not be suitable?

Reasons to defer or avoid glans injection can include active infection or skin disease, unresolved previous filler complications, significant vascular/healing risk, unrealistic expectations, uncertain indication, or a situation in which a more established PE pathway has not been assessed.

What are the risks?

Potential adverse effects include:

• pain, swelling and bruising;
• irregular contour or nodules;
• altered sensation or numbness;
• infection;
• tissue inflammation;
• vascular compromise and tissue necrosis;
• dissatisfaction or need for further treatment.

A 2019 paper specifically reported complications of glans augmentation, which is one reason EAU guidance remains cautious even though efficacy studies exist.

How long does glans filler last?

HA is biodegradable, but durability data are not uniform. A five-year follow-up from an older cohort reported residual augmentation and persistent changes in sensitivity in some patients, but that small long-term series should not be generalised to every HA product or technique.

When is prompt assessment needed?

Severe pain, marked colour change, blistering, rapidly worsening swelling, fever, discharge, difficulty urinating or any concern about glans circulation after injection warrants prompt medical assessment.

Medical information note

Glans HA injection has clinical evidence, particularly for PE, but it remains a cautious option rather than a first-line universal treatment. Purely aesthetic glans augmentation has a more limited evidence base.